marketcaparena
Search

    LLY

    ELI LILLY & Co

    Company overview

    Market capitalization
    $1.12T
    Employees
    50,000
    Latest publication
    2026-09-29
    About ELI LILLY & Co

    Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue22,974,000,000USD19,799,000,000USD19,292,000,000USD17,600,800,000USD15,557,700,000USD12,728,500,000USD13,532,800,000USD11,439,100,000USD
    Cost Of Revenue3,268,000,000USD3,577,000,000USD2,883,700,000USD3,008,300,000USD2,447,800,000USD2,224,200,000USD2,403,800,000USD2,170,800,000USD
    Gross Profit19,706,000,000USD16,222,000,000USD16,408,300,000USD14,592,500,000USD13,109,900,000USD10,504,300,000USD11,129,000,000USD9,268,300,000USD
    Research Development3,819,000,000USD3,510,000,000USD3,802,000,000USD3,465,700,000USD3,336,100,000USD2,733,700,000USD3,022,500,000USD2,734,100,000USD
    Selling General Administrative3,430,000,000USD2,934,000,000USD3,343,500,000USD2,740,700,000USD2,647,600,000USD2,362,200,000USD2,308,700,000USD1,984,400,000USD
    Other Operating Expenses3,479,000,000USD279,000,000USD——————
    Total Operating Expenses10,728,000,000USD6,723,000,000USD7,633,000,000USD6,206,400,000USD5,983,700,000USD5,095,900,000USD5,331,200,000USD4,718,500,000USD
    Operating Income8,978,000,000USD9,499,000,000USD8,775,300,000USD8,386,100,000USD7,126,200,000USD5,408,400,000USD5,797,800,000USD4,549,800,000USD
    Total Other Income Expense Net269,000,000USD-649,000,000USD-509,200,000USD-1,153,700,000USD-349,800,000USD-1,952,300,000USD-759,100,000USD-2,961,400,000USD
    Income Before Tax9,247,000,000USD8,850,000,000USD8,265,000,000USD7,232,400,000USD6,776,400,000USD3,456,100,000USD5,038,700,000USD1,588,400,000USD
    Income Tax Expense2,152,000,000USD1,454,000,000USD1,629,000,000USD1,649,900,000USD1,115,900,000USD696,800,000USD628,900,000USD618,100,000USD
    Net Income7,095,000,000USD7,396,000,000USD6,636,000,000USD5,582,500,000USD5,660,500,000USD2,759,300,000USD4,409,800,000USD970,300,000USD
    Unclassified Operating Expenses——487,500,000USD—————
    Interest Income——123,000,000USD65,000,000USD40,000,000USD48,300,000USD44,300,000USD47,800,000USD
    Interest Expense——123,000,000USD179,600,000USD249,000,000USD243,700,000USD224,700,000USD192,700,000USD
    Tax Provision——1,629,000,000USD1,649,900,000USD1,115,900,000USD696,800,000USD628,900,000USD618,100,000USD
    Net Income From Continuing Ops——6,637,700,000USD5,582,500,000USD5,660,500,000USD2,759,300,000USD4,409,800,000USD970,300,000USD
    Ebit——8,235,800,000USD7,412,000,000USD7,025,400,000USD3,699,800,000USD5,263,400,000USD1,781,100,000USD
    Ebitda——8,388,000,000USD7,882,000,000USD7,503,900,000USD4,162,600,000USD5,748,200,000USD2,247,900,000USD
    Depreciation And Amortization——152,200,000USD470,000,000USD478,500,000USD462,800,000USD484,800,000USD466,800,000USD
    Reconciled Depreciation——585,700,000USD470,000,000USD478,500,000USD462,800,000USD484,800,000USD466,800,000USD
    Net Income Applicable To Common Shares——6,636,000,000USD5,582,500,000USD5,660,500,000USD2,759,300,000USD4,409,800,000USD970,300,000USD
    Net Interest Income———-114,600,000USD-209,000,000USD-195,400,000USD-180,400,000USD-144,900,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue65,179,000,000USD45,042,700,000USD34,124,100,000USD28,541,400,000USD28,318,400,000USD24,539,800,000USD22,319,500,000USD21,493,300,000USD
    Cost Of Revenue10,564,000,000USD8,418,300,000USD7,082,200,000USD6,629,800,000USD7,312,800,000USD5,483,300,000USD4,721,200,000USD4,681,700,000USD
    Gross Profit54,615,000,000USD36,624,400,000USD27,041,900,000USD21,911,600,000USD21,005,600,000USD19,056,500,000USD17,598,300,000USD16,811,600,000USD
    Research Development13,337,500,000USD10,990,600,000USD9,313,400,000USD7,190,800,000USD6,930,700,000USD5,976,300,000USD5,595,000,000USD5,051,200,000USD
    Selling General Administrative11,094,000,000USD8,132,100,000USD6,941,200,000USD6,067,500,000USD6,141,900,000USD5,869,400,000USD6,003,900,000USD5,734,600,000USD
    Unclassified Operating Expenses487,500,000USD———————
    Total Operating Expenses24,919,000,000USD19,122,700,000USD16,254,600,000USD13,258,300,000USD13,072,600,000USD11,845,700,000USD11,598,900,000USD10,785,800,000USD
    Operating Income29,696,000,000USD17,501,700,000USD10,787,300,000USD8,653,300,000USD7,933,000,000USD7,210,800,000USD5,999,400,000USD6,025,800,000USD
    Interest Income642,000,000USD175,200,000USD173,600,000USD268,800,000USD314,400,000USD326,600,000USD80,400,000USD161,300,000USD
    Interest Expense795,300,000USD780,600,000USD485,900,000USD331,600,000USD339,800,000USD359,600,000USD400,600,000USD242,500,000USD
    Income Before Tax25,729,900,000USD12,680,400,000USD6,554,600,000USD6,806,400,000USD6,155,500,000USD7,229,900,000USD5,265,900,000USD3,680,100,000USD
    Income Tax Expense5,091,600,000USD2,090,400,000USD1,314,200,000USD561,600,000USD573,800,000USD1,036,200,000USD628,000,000USD529,500,000USD
    Tax Provision5,091,000,000USD2,090,400,000USD1,314,200,000USD561,600,000USD573,800,000USD1,036,200,000USD628,000,000USD563,700,000USD
    Net Income20,638,300,000USD10,590,000,000USD5,240,400,000USD6,244,800,000USD5,581,700,000USD6,193,700,000USD8,318,400,000USD3,232,000,000USD
    Net Income From Continuing Ops20,640,000,000USD10,590,000,000USD5,240,400,000USD6,244,800,000USD5,581,700,000USD6,193,700,000USD4,637,900,000USD3,232,000,000USD
    Ebit26,373,000,000USD13,461,000,000USD7,040,500,000USD7,138,000,000USD6,495,300,000USD7,589,500,000USD5,666,500,000USD3,922,600,000USD
    Ebitda27,936,500,000USD15,227,600,000USD8,567,800,000USD8,660,500,000USD8,042,900,000USD8,913,400,000USD6,899,100,000USD5,531,600,000USD
    Depreciation And Amortization1,563,500,000USD1,766,600,000USD1,527,300,000USD1,522,500,000USD1,547,600,000USD1,323,900,000USD1,232,600,000USD1,609,000,000USD
    Reconciled Depreciation1,997,000,000USD1,766,600,000USD1,527,300,000USD1,522,500,000USD1,547,600,000USD1,323,900,000USD1,232,600,000USD1,609,000,000USD
    Total Other Income Expense Net-3,965,000,000USD-4,821,300,000USD-4,232,700,000USD-1,846,900,000USD-1,777,500,000USD19,100,000USD-733,500,000USD-2,345,700,000USD
    Net Income Applicable To Common Shares20,640,000,000USD10,590,000,000USD5,240,400,000USD6,244,800,000USD5,581,700,000USD6,193,700,000USD8,318,400,000USD3,232,000,000USD
    Net Interest Income—-605,400,000USD-312,300,000USD-268,800,000USD-314,400,000USD-326,600,000USD-320,200,000USD-110,800,000USD
    Non Operating Income Net Other———-320,900,000USD——291,600,000USD74,800,000USD
    Minority Interest—————183,600,000USD92,200,000USD1,080,400,000USD
    Discontinued Operations——————3,680,500,000USD81,400,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets142,283,000,000USD116,576,000,000USD112,476,000,000USD114,935,400,000USD100,922,600,000USD89,388,800,000USD78,714,900,000USD75,606,900,000USD
    Cash And Equivalents8,950,000,000USD5,282,000,000USD7,268,000,000USD9,791,900,000USD3,375,900,000USD3,093,300,000USD3,268,400,000USD3,369,000,000USD
    Long Term Investments3,856,000,000USD3,116,000,000USD2,802,000,000USD2,808,300,000USD3,207,400,000USD3,222,700,000USD3,215,900,000USD3,200,200,000USD
    Total Current Assets64,672,000,000USD54,835,000,000USD55,629,000,000USD62,071,300,000USD49,854,000,000USD41,261,200,000USD32,739,700,000USD31,415,100,000USD
    Other Current Assets86,000,000USD214,000,000USD14,462,000,000USD20,520,200,000USD18,088,600,000USD14,726,300,000USD8,451,900,000USD8,385,200,000USD
    Other Non Current Assets7,482,000,000USD7,231,000,000USD——————
    Total Liabilities108,404,000,000USD85,378,000,000USD——————
    Total Current Liabilities47,741,000,000USD36,634,000,000USD35,228,000,000USD40,140,900,000USD39,019,900,000USD30,068,100,000USD28,376,600,000USD24,674,100,000USD
    Other Current Liabilities11,659,000,000USD8,699,000,000USD——————
    Other Non Current Liabilities7,344,000,000USD4,085,000,000USD——————
    Total Stockholder Equity33,879,000,000USD31,198,000,000USD26,535,000,000USD23,793,300,000USD18,272,900,000USD15,764,800,000USD14,192,100,000USD14,240,000,000USD
    Total Equity Including Noncontrolling Interest33,879,000,000USD31,198,000,000USD——————
    Long Term Debt47,858,000,000USD39,370,000,000USD40,868,000,000USD40,873,600,000USD34,180,100,000USD34,499,500,000USD28,527,100,000USD29,045,400,000USD
    Net Receivables20,083,000,000USD18,429,000,000USD20,155,000,000USD19,457,200,000USD17,205,600,000USD14,003,200,000USD13,275,400,000USD12,051,700,000USD
    Inventory16,793,000,000USD14,529,000,000USD13,744,000,000USD12,180,400,000USD11,013,800,000USD9,311,000,000USD7,589,200,000USD7,459,800,000USD
    Property Plant Equipment Net29,286,000,000USD26,540,000,000USD24,674,000,000USD22,316,000,000USD20,529,700,000USD18,474,100,000USD17,102,400,000USD16,171,800,000USD
    Goodwill8,849,000,000USD6,130,000,000USD——————
    Intangible Assets18,110,000,000USD7,374,000,000USD6,522,000,000USD6,446,700,000USD5,908,300,000USD6,012,200,000USD6,166,300,000USD6,537,300,000USD
    Accounts Payable6,112,000,000USD5,029,000,000USD5,379,000,000USD4,262,200,000USD4,075,700,000USD3,442,000,000USD3,228,600,000USD2,886,500,000USD
    Short Term Debt7,050,000,000USD4,000,000,000USD1,635,000,000USD1,633,000,000USD5,723,700,000USD4,016,400,000USD5,117,100,000USD2,074,300,000USD
    Common Stock588,000,000USD590,000,000USD590,000,000USD591,400,000USD592,000,000USD592,600,000USD592,400,000USD593,900,000USD
    Retained Earnings31,893,000,000USD29,514,000,000USD24,470,000,000USD22,252,000,000USD17,376,200,000USD15,099,500,000USD13,545,000,000USD13,627,200,000USD
    Accumulated Other Comprehensive Income-2,761,000,000USD-2,833,000,000USD-2,880,000,000USD-3,206,300,000USD-3,716,000,000USD-3,774,600,000USD-4,321,900,000USD-4,274,800,000USD
    Total Liab——85,941,000,000USD91,084,600,000USD82,573,500,000USD73,542,000,000USD64,443,300,000USD61,286,200,000USD
    Other Current Liab——28,214,000,000USD24,801,300,000USD22,262,500,000USD16,434,000,000USD20,030,900,000USD15,834,500,000USD
    Capital Stock——590,000,000USD591,400,000USD592,000,000USD592,600,000USD592,400,000USD593,900,000USD
    Good Will——5,898,000,000USD5,898,000,000USD5,770,500,000USD5,770,500,000USD5,770,300,000USD5,768,400,000USD
    Other Assets——16,951,000,000USD15,395,100,000USD15,652,700,000USD14,648,100,000USD29,221,300,000USD12,514,100,000USD
    Cash——7,163,000,000USD9,791,900,000USD3,375,900,000USD3,093,300,000USD3,268,400,000USD3,369,000,000USD
    Cash And Short Term Investments——7,268,000,000USD9,913,500,000USD3,546,000,000USD3,220,700,000USD3,423,200,000USD3,518,400,000USD
    Net Debt——35,340,000,000USD32,714,700,000USD36,527,900,000USD35,422,600,000USD30,375,800,000USD27,750,700,000USD
    Short Long Term Debt——1,635,000,000USD1,633,000,000USD5,723,700,000USD4,016,400,000USD5,117,100,000USD2,074,300,000USD
    Short Long Term Debt Total——42,503,000,000USD42,506,600,000USD39,903,800,000USD38,515,900,000USD33,644,200,000USD31,119,700,000USD
    Short Term Investments——105,000,000USD121,600,000USD170,100,000USD127,400,000USD154,800,000USD149,400,000USD
    Property Plant Equipment Gross——37,234,000,000USD34,726,900,000USD33,083,700,000USD30,621,000,000USD28,891,400,000USD27,987,800,000USD
    Common Stock Shares Outstanding——898,002,000shares898,800,000shares899,793,000shares900,604,000shares903,158,000shares905,000,000shares
    Non Current Assets Total——56,847,000,000USD52,864,100,000USD51,068,600,000USD48,127,600,000USD45,975,200,000USD44,191,800,000USD
    Non Current Liabilities Total——50,713,000,000USD50,943,700,000USD43,553,600,000USD43,473,900,000USD36,066,700,000USD36,612,100,000USD
    Non Current Liabilities Other——3,970,000,000USD3,776,500,000USD2,344,700,000USD2,288,400,000USD2,178,200,000USD2,239,400,000USD
    Non Currrent Assets Other——6,992,000,000USD6,432,400,000USD6,225,300,000USD6,074,900,000USD5,719,700,000USD5,121,800,000USD
    Net Working Capital——20,401,000,000USD21,930,400,000USD10,834,100,000USD11,193,100,000USD4,363,100,000USD6,741,000,000USD
    Unclassified Non Current Assets——-6,992,000,000USD-6,432,400,000USD-6,225,300,000USD-6,074,900,000USD-21,220,700,000USD-5,121,800,000USD
    Unclassified Current Liabilities——-1,635,000,000USD7,811,400,000USD1,234,300,000USD2,159,300,000USD-5,117,100,000USD-2,074,300,000USD
    Unclassified Non Current Liabilities——5,875,000,000USD6,293,600,000USD7,028,800,000USD6,686,000,000USD5,361,400,000USD5,327,300,000USD
    Unclassified Equity——3,765,000,000USD3,564,800,000USD3,428,700,000USD3,254,700,000USD3,784,200,000USD3,699,800,000USD
    Current Deferred Revenue———————3,878,800,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets112,476,000,000USD78,714,900,000USD64,006,300,000USD49,489,800,000USD48,806,000,000USD46,633,100,000USD39,286,100,000USD43,908,400,000USD
    Intangible Assets6,521,000,000USD6,166,300,000USD6,906,600,000USD7,206,600,000USD7,691,900,000USD7,450,000,000USD6,618,000,000USD1,068,000,000USD
    Other Current Assets14,462,000,000USD8,451,900,000USD5,690,300,000USD2,954,100,000USD2,530,600,000USD2,871,500,000USD2,538,900,000USD2,146,500,000USD
    Total Liab85,941,000,000USD64,443,300,000USD53,142,600,000USD38,714,400,000USD39,651,200,000USD40,807,900,000USD36,587,000,000USD32,999,300,000USD
    Total Stockholder Equity26,535,000,000USD14,192,100,000USD10,771,900,000USD10,649,800,000USD8,979,200,000USD5,641,600,000USD2,606,900,000USD10,909,100,000USD
    Other Current Liab22,339,000,000USD20,030,900,000USD13,940,700,000USD13,231,400,000USD11,716,900,000USD10,371,100,000USD8,710,000,000USD9,174,800,000USD
    Common Stock590,000,000USD592,400,000USD593,600,000USD594,100,000USD596,300,000USD598,200,000USD598,800,000USD661,000,000USD
    Capital Stock590,000,000USD592,400,000USD593,600,000USD594,100,000USD596,300,000USD598,200,000USD598,800,000USD661,000,000USD
    Retained Earnings24,470,000,000USD13,545,000,000USD10,312,300,000USD10,042,600,000USD8,958,500,000USD7,830,200,000USD4,920,400,000USD11,395,900,000USD
    Good Will5,898,000,000USD5,770,300,000USD4,939,700,000USD4,073,000,000USD3,892,000,000USD3,766,500,000USD3,679,400,000USD1,366,600,000USD
    Other Assets15,691,000,000USD29,221,300,000USD10,467,200,000USD7,129,900,000USD6,380,000,000USD9,274,000,000USD4,748,300,000USD10,910,000,000USD
    Cash7,163,000,000USD3,268,400,000USD2,818,600,000USD2,067,000,000USD3,818,500,000USD3,657,100,000USD2,337,500,000USD7,320,700,000USD
    Cash And Equivalents7,268,000,000USD3,268,400,000USD2,818,600,000USD2,067,000,000USD3,818,500,000USD3,657,100,000USD2,337,500,000USD7,320,700,000USD
    Cash And Short Term Investments7,268,000,000USD3,423,200,000USD2,927,700,000USD2,211,800,000USD3,908,600,000USD3,681,300,000USD2,438,500,000USD7,408,900,000USD
    Total Current Assets55,629,000,000USD32,739,700,000USD25,727,000,000USD18,034,500,000USD18,452,400,000USD17,462,100,000USD13,709,600,000USD20,549,600,000USD
    Total Current Liabilities35,228,000,000USD28,376,600,000USD27,293,200,000USD17,138,200,000USD15,052,700,000USD12,481,600,000USD11,775,200,000USD11,888,100,000USD
    Net Debt35,340,000,000USD30,375,800,000USD22,406,700,000USD14,171,600,000USD13,066,200,000USD12,938,200,000USD13,466,400,000USD2,977,900,000USD
    Short Term Debt1,635,000,000USD5,117,100,000USD6,904,500,000USD1,501,100,000USD1,538,300,000USD8,700,000USD1,499,300,000USD1,102,200,000USD
    Short Long Term Debt1,635,000,000USD5,117,100,000USD6,904,500,000USD1,501,100,000USD1,538,300,000USD8,700,000USD1,499,300,000USD1,131,200,000USD
    Short Long Term Debt Total42,503,000,000USD33,644,200,000USD25,225,300,000USD16,238,600,000USD16,884,700,000USD16,595,300,000USD15,803,900,000USD12,741,900,000USD
    Long Term Debt40,868,000,000USD28,527,100,000USD18,320,800,000USD14,737,500,000USD15,346,400,000USD16,586,600,000USD13,817,900,000USD11,639,700,000USD
    Long Term Investments2,802,000,000USD3,215,900,000USD3,052,200,000USD2,901,800,000USD3,212,600,000USD2,966,800,000USD1,962,400,000USD2,020,700,000USD
    Short Term Investments105,000,000USD154,800,000USD109,100,000USD144,800,000USD90,100,000USD24,200,000USD101,000,000USD88,200,000USD
    Net Receivables20,155,000,000USD13,275,400,000USD11,336,200,000USD8,558,900,000USD8,127,200,000USD6,929,000,000USD5,541,500,000USD5,776,800,000USD
    Inventory13,744,000,000USD7,589,200,000USD5,772,800,000USD4,309,700,000USD3,886,000,000USD3,980,300,000USD3,190,700,000USD3,098,100,000USD
    Accounts Payable5,379,000,000USD3,228,600,000USD2,598,800,000USD1,930,600,000USD1,670,600,000USD1,606,700,000USD1,405,300,000USD1,207,100,000USD
    Property Plant Equipment Net24,675,000,000USD17,102,400,000USD12,913,600,000USD10,144,000,000USD8,985,100,000USD8,681,900,000USD8,405,000,000USD7,996,100,000USD
    Property Plant Equipment Gross37,234,000,000USD28,891,400,000USD24,012,900,000USD20,377,400,000USD18,961,800,000USD8,681,900,000USD8,405,000,000USD8,919,500,000USD
    Accumulated Other Comprehensive Income-2,880,000,000USD-4,321,900,000USD-4,327,000,000USD-3,844,600,000USD-4,343,100,000USD-9,509,600,000USD-6,523,600,000USD-5,729,200,000USD
    Common Stock Shares Outstanding898,002,000shares904,059,000shares903,284,000shares950,182,000shares953,653,000shares956,590,000shares957,526,000shares1,033,667,000shares
    Non Current Assets Total56,847,000,000USD45,975,200,000USD38,279,300,000USD31,455,300,000USD30,353,600,000USD29,171,000,000USD25,576,500,000USD23,358,800,000USD
    Non Current Liabilities Total50,713,000,000USD36,066,700,000USD25,849,400,000USD21,576,200,000USD24,598,500,000USD28,326,300,000USD24,811,800,000USD21,111,200,000USD
    Non Current Liabilities Other3,970,000,000USD2,178,200,000USD2,240,600,000USD6,751,400,000USD1,644,300,000USD1,707,500,000USD8,806,400,000USD9,471,500,000USD
    Non Currrent Assets Other6,992,000,000USD5,719,700,000USD4,989,900,000USD4,337,000,000USD4,082,700,000USD3,475,400,000USD2,339,100,000USD8,309,000,000USD
    Net Working Capital20,401,000,000USD4,363,100,000USD-1,566,200,000USD896,300,000USD3,399,700,000USD4,980,500,000USD1,934,400,000USD8,661,500,000USD
    Unclassified Non Current Assets-5,732,000,000USD-21,220,700,000USD-4,989,900,000USD-4,337,000,000USD-3,890,700,000USD-6,443,600,000USD-2,175,700,000USD-8,311,600,000USD
    Unclassified Current Liabilities4,240,000,000USD-5,117,100,000USD-17,563,900,000USD-1,026,000,000USD-10,227,700,000USD-7,629,500,000USD-8,019,900,000USD-1,131,200,000USD
    Unclassified Non Current Liabilities5,875,000,000USD5,361,400,000USD5,288,000,000USD-6,130,400,000USD-1,066,400,000USD-996,800,000USD-10,481,400,000USD-11,870,000,000USD
    Unclassified Equity3,765,000,000USD3,784,200,000USD-3,606,800,000USD-3,607,300,000USD-3,609,500,000USD-598,200,000USD-3,612,000,000USD-2,593,800,000USD
    Current Deferred Revenue——14,508,600,000USD—8,816,300,000USD8,115,900,000USD6,681,200,000USD404,000,000USD
    Additional Paid In Capital——7,250,400,000USD6,921,400,000USD6,833,400,000USD6,778,500,000USD6,685,300,000USD6,583,600,000USD
    Treasury Stock——-44,200,000USD-50,500,000USD-52,700,000USD-55,700,000USD-60,800,000USD-69,400,000USD
    Deferred Long Term Liab———87,300,000USD——2,187,500,000USD—
    Other Liab———6,130,400,000USD8,674,200,000USD11,029,000,000USD10,481,400,000USD11,870,000,000USD
    Net Tangible Assets———-629,800,000USD-4,014,800,000USD-5,574,900,000USD-7,690,500,000USD1,960,200,000USD
    Unclassified Current Assets———————2,119,300,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Net Income14,491,000,000USD
    Depreciation1,043,000,000USD
    Stock Based Compensation362,000,000USD
    Deferred Income Tax-433,000,000USD
    Other Non Cash Items3,360,000,000USD
    Unclassified Operating Cash Flow-466,000,000USD
    Change In Working Capital-2,334,000,000USD
    Operating Cash Flow16,023,000,000USD
    Capital Expenditures-5,259,000,000USD
    Net Investments-604,000,000USD
    Other Investing Activities-158,000,000USD
    Unclassified Investing Cash Flow-13,291,000,000USD
    Investing Cash Flow-19,312,000,000USD
    Net Debt Issuance12,602,000,000USD
    Net Common Stock Issuance-3,957,000,000USD
    Common Dividends Paid-3,094,000,000USD
    Other Financing Activities-595,000,000USD
    Financing Cash Flow4,956,000,000USD
    Effect Of Forex Changes On Cash15,000,000USD
    Change In Cash1,682,000,000USD
    End Cash Flow8,950,000,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Depreciation509,000,000USD585,700,000USD470,000,000USD478,500,000USD462,800,000USD484,800,000USD466,800,000USD414,400,000USD
    Stock Based Compensation161,000,000USD136,100,000USD151,100,000USD185,100,000USD153,700,000USD141,900,000USD133,200,000USD211,100,000USD
    Operating Cash Flow5,333,000,000USD———————
    Net Investments-297,000,000USD———————
    Other Investing Activities31,000,000USD———————
    Unclassified Investing Cash Flow-3,650,000,000USD-111,600,000USD975,400,000USD1,974,800,000USD4,984,200,000USD2,086,800,000USD6,807,800,000USD1,307,200,000USD
    Investing Cash Flow-3,916,000,000USD———————
    Net Debt Issuance1,025,000,000USD———————
    Net Common Stock Issuance-2,356,000,000USD———————
    Common Dividends Paid-1,548,000,000USD———————
    Other Financing Activities-591,000,000USD———————
    Financing Cash Flow-3,470,000,000USD———————
    Effect Of Forex Changes On Cash67,000,000USD———————
    Change In Cash-1,986,000,000USD-2,523,900,000USD6,416,000,000USD282,600,000USD-175,100,000USD-100,600,000USD145,400,000USD763,400,000USD
    End Cash Flow5,282,000,000USD———————
    Net Income—6,637,700,000USD5,582,500,000USD5,660,500,000USD2,759,300,000USD4,409,800,000USD970,300,000USD2,967,000,000USD
    Other Non Cash Items—287,300,000USD922,700,000USD94,400,000USD2,045,600,000USD628,900,000USD2,581,200,000USD280,400,000USD
    Change In Working Capital—-3,674,100,000USD1,208,200,000USD-2,262,900,000USD-3,364,200,000USD-2,224,900,000USD-9,800,000USD-1,399,100,000USD
    Total Cash From Operating Activities—3,224,600,000USD8,835,900,000USD3,086,900,000USD1,665,600,000USD2,473,800,000USD3,711,900,000USD1,466,200,000USD
    Capital Expenditures—-2,546,700,000USD-223,900,000USD-1,803,900,000USD-3,266,500,000USD-1,747,200,000USD-4,170,800,000USD-1,402,800,000USD
    Free Cash Flow—677,900,000USD8,612,000,000USD1,283,000,000USD-1,600,900,000USD726,600,000USD-458,900,000USD63,400,000USD
    Investments—5,000,000USD-2,982,600,000USD-1,834,900,000USD-3,352,300,000USD-1,920,500,000USD-4,004,700,000USD-2,198,700,000USD
    Total Cashflows From Investing Activities—-2,802,200,000USD-2,982,600,000USD-1,834,900,000USD-3,352,300,000USD-1,920,500,000USD-4,004,700,000USD-2,198,700,000USD
    Net Borrowings—-500,000USD2,614,500,000USD824,700,000USD4,612,300,000USD3,042,300,000USD1,875,200,000USD—
    Total Cash From Financing Activities—-2,878,800,000USD531,000,000USD-1,244,900,000USD1,379,700,000USD-225,400,000USD211,300,000USD1,555,500,000USD
    Dividends Paid—-1,345,500,000USD-1,345,200,000USD-1,347,000,000USD-1,346,300,000USD-1,168,300,000USD-1,170,500,000USD-1,172,400,000USD
    Sale Purchase Of Stock—-1,507,700,000USD-708,100,000USD-692,200,000USD-1,200,000,000USD-2,053,900,000USD-446,100,000USD0USD
    Begin Period Cash Flow—9,791,900,000USD3,375,900,000USD3,093,300,000USD3,268,400,000USD3,369,000,000USD3,223,600,000USD2,460,200,000USD
    End Period Cash Flow—7,268,000,000USD9,791,900,000USD3,375,900,000USD3,093,300,000USD3,268,400,000USD3,369,000,000USD3,223,600,000USD
    Other Cashflows From Investing Activities—-148,900,000USD-751,500,000USD-170,900,000USD-1,717,700,000USD-339,600,000USD-2,637,000,000USD95,600,000USD
    Other Cashflows From Financing Activities—-25,100,000USD-30,200,000USD-30,400,000USD-686,300,000USD-45,500,000USD-47,300,000USD-8,000,000USD
    Unclassified Operating Cash Flow—-748,100,000USD501,400,000USD-1,068,700,000USD-391,600,000USD-966,700,000USD-429,800,000USD-1,007,600,000USD
    Unclassified Financing Cash Flow———————2,735,900,000USD
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income20,640,000,000USD10,590,000,000USD5,240,400,000USD6,244,800,000USD5,581,700,000USD6,193,700,000USD8,318,400,000USD3,232,000,000USD
    Depreciation1,997,000,000USD1,766,600,000USD1,527,300,000USD1,522,500,000USD1,547,600,000USD1,323,900,000USD1,232,600,000USD1,609,000,000USD
    Stock Based Compensation626,000,000USD645,600,000USD628,500,000USD371,100,000USD342,800,000USD308,100,000USD312,400,000USD279,500,000USD
    Other Non Cash Items3,350,000,000USD3,883,800,000USD2,239,900,000USD1,145,700,000USD1,613,500,000USD-444,200,000USD-3,402,000,000USD2,455,900,000USD
    Change To Account Receivables-7,000,000,000USD-2,155,200,000USD-2,451,000,000USD-299,600,000USD-1,278,300,000USD-1,350,000,000USD-127,200,000USD-10,763,500,000USD
    Change To Inventory-4,671,000,000USD-2,507,400,000USD-1,425,000,000USD-599,700,000USD-235,900,000USD-533,400,000USD-258,700,000USD7,800,000USD
    Change In Working Capital-8,093,000,000USD-5,385,000,000USD-3,055,000,000USD-14,500,000USD-1,022,600,000USD-747,400,000USD-1,687,200,000USD-2,378,700,000USD
    Total Cash From Operating Activities16,813,000,000USD8,817,900,000USD4,240,100,000USD7,084,400,000USD7,260,700,000USD6,499,600,000USD4,836,600,000USD5,524,500,000USD
    Capital Expenditures-7,841,000,000USD-8,403,600,000USD-7,392,100,000USD-2,484,000,000USD-1,873,200,000USD-2,029,100,000USD-1,353,500,000USD-3,018,200,000USD
    Free Cash Flow8,972,000,000USD414,300,000USD-3,152,000,000USD4,600,400,000USD5,387,500,000USD4,470,500,000USD3,483,100,000USD2,506,300,000USD
    Investments319,000,000USD-9,301,500,000USD-7,152,700,000USD-244,000,000USD-166,000,000USD516,700,000USD456,200,000USD5,111,900,000USD
    Total Cashflows From Investing Activities-10,972,000,000USD-9,301,500,000USD-7,152,700,000USD-3,762,900,000USD-2,867,500,000USD-2,258,900,000USD-8,082,900,000USD1,906,000,000USD
    Net Borrowings8,051,000,000USD8,901,100,000USD8,649,900,000USD-62,000,000USD501,400,000USD291,600,000USD4,685,400,000USD-729,300,000USD
    Total Cash From Financing Activities-2,213,000,000USD1,230,100,000USD3,495,600,000USD-5,406,700,000USD-4,131,300,000USD-3,137,100,000USD-2,324,500,000USD-5,904,900,000USD
    Dividends Paid-5,384,000,000USD-4,680,400,000USD-4,069,300,000USD-3,535,800,000USD-3,086,800,000USD-2,687,100,000USD-2,409,800,000USD-2,311,800,000USD
    Sale Purchase Of Stock-4,108,000,000USD-2,500,000,000USD-750,000,000USD-1,500,000,000USD-1,250,000,000USD-500,000,000USD-4,400,000,000USD-4,150,700,000USD
    Change In Cash4,000,000,000USD449,800,000USD751,600,000USD-1,751,500,000USD161,400,000USD1,319,600,000USD-5,660,700,000USD1,462,000,000USD
    Begin Period Cash Flow3,268,000,000USD2,818,600,000USD2,067,000,000USD3,818,500,000USD3,657,100,000USD2,337,500,000USD7,998,200,000USD6,536,200,000USD
    End Period Cash Flow7,268,000,000USD3,268,400,000USD2,818,600,000USD2,067,000,000USD3,818,500,000USD3,657,100,000USD2,337,500,000USD7,998,200,000USD
    Other Cashflows From Investing Activities-2,789,000,000USD-3,042,700,000USD-2,532,100,000USD-1,163,300,000USD24,300,000USD102,800,000USD-7,505,200,000USD-1,995,300,000USD
    Other Cashflows From Financing Activities-772,000,000USD-490,600,000USD-335,000,000USD1,189,100,000USD-295,900,000USD-241,600,000USD-200,100,000USD-372,800,000USD
    Unclassified Operating Cash Flow-1,707,000,000USD-2,683,100,000USD-2,341,000,000USD-2,185,200,000USD-802,300,000USD-134,500,000USD62,400,000USD326,800,000USD
    Unclassified Investing Cash Flow-661,000,000USD11,446,300,000USD9,924,200,000USD128,400,000USD-852,600,000USD-849,300,000USD319,600,000USD1,807,600,000USD
    Change To Liabilities———1,678,300,000USD-664,100,000USD1,271,300,000USD-699,000,000USD-409,800,000USD
    Cash And Cash Equivalents Changes———-1,583,900,000USD——-5,660,700,000USD1,462,000,000USD
    Unclassified Financing Cash Flow———-1,498,000,000USD———1,659,700,000USD
    Exchange Rate Changes——————-89,900,000USD-63,600,000USD
    Issuance Of Capital Stock———————1,659,700,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q3 2018Quarterly · 2018-09-30SegmentAnimal Health Products772,700,000USD0000059478-18-000256
    Q3 2018Quarterly · 2018-09-30SegmentHuman Pharmaceutical Products5,289,200,000USD0000059478-18-000256
    Q2 2018Quarterly · 2018-06-30SegmentAnimal Health Products792,100,000USD0000059478-18-000188
    Q2 2018Quarterly · 2018-06-30SegmentHuman Pharmaceutical Products5,563,200,000USD0000059478-18-000188
    Q1 2018Quarterly · 2018-03-31SegmentAnimal Health Products761,300,000USD0000059478-18-000136
    Q1 2018Quarterly · 2018-03-31SegmentHuman Pharmaceutical Products4,938,700,000USD0000059478-18-000136
    Q4 2017Quarterly · 2017-12-31SegmentAnimal Health Products790,800,000USDLegacy provider
    Q4 2017Quarterly · 2017-12-31SegmentHuman Pharmaceutical Products5,369,900,000USDLegacy provider
    FY 2017Yearly · 2017-12-31SegmentAnimal Health Products3,085,600,000USD0000059478-18-000089
    FY 2017Yearly · 2017-12-31SegmentHuman Pharmaceutical Products19,785,700,000USD0000059478-18-000089
    Q3 2017Quarterly · 2017-09-30SegmentAnimal Health Products740,600,000USD0000059478-18-000256
    Q3 2017Quarterly · 2017-09-30SegmentHuman Pharmaceutical Products4,917,400,000USD0000059478-18-000256
    Q3 2017Quarterly · 2017-09-30ProductCollaborationand Other Revenue334,200,000USD0000059478-18-000256
    Q3 2017Quarterly · 2017-09-30ProductProduct5,323,800,000USD0000059478-18-000256
    Q3 2017Quarterly · 2017-09-30ProductRoyalty36,700,000USD0000059478-18-000256
    Q2 2017Quarterly · 2017-06-30SegmentAnimal Health Products784,800,000USD0000059478-18-000188
    Q2 2017Quarterly · 2017-06-30SegmentHuman Pharmaceutical Products5,039,400,000USD0000059478-18-000188
    Q2 2017Quarterly · 2017-06-30ProductCollaborationand Other Revenue294,500,000USD0000059478-18-000188
    Q2 2017Quarterly · 2017-06-30ProductProduct5,529,800,000USD0000059478-18-000188
    Q2 2017Quarterly · 2017-06-30ProductRoyalty35,000,000USD0000059478-18-000188
    Q1 2017Quarterly · 2017-03-31SegmentAnimal Health Products769,400,000USD0000059478-18-000136
    Q1 2017Quarterly · 2017-03-31SegmentHuman Pharmaceutical Products4,459,000,000USD0000059478-18-000136
    Q4 2016Quarterly · 2016-12-31SegmentAnimal Health Products837,600,000USDLegacy provider
    Q4 2016Quarterly · 2016-12-31SegmentHuman Pharmaceutical Products4,922,900,000USDLegacy provider
    FY 2016Yearly · 2016-12-31SegmentAnimal Health Products3,158,200,000USD0000059478-18-000089
    FY 2016Yearly · 2016-12-31SegmentHuman Pharmaceutical Products18,063,900,000USD0000059478-18-000089
    FY 2016Yearly · 2016-12-31GeographyEurope3,768,100,000USD0000059478-18-000089
    FY 2016Yearly · 2016-12-31GeographyJapan2,330,900,000USD0000059478-18-000089
    FY 2016Yearly · 2016-12-31GeographyOther Foreign Countries3,616,900,000USD0000059478-18-000089
    FY 2016Yearly · 2016-12-31GeographyUnited States11,506,200,000USD0000059478-18-000089
    FY 2015Yearly · 2015-12-31SegmentAnimal Health Products3,181,000,000USD0000059478-16-000321
    FY 2015Yearly · 2015-12-31SegmentPharmaceutical Products Total — Cardiovascular3,068,000,000USD0000059478-16-000321
    FY 2015Yearly · 2015-12-31SegmentPharmaceutical Products Total — Endocrinology7,036,800,000USD0000059478-16-000321
    FY 2015Yearly · 2015-12-31SegmentPharmaceutical Products Total — Neuroscience2,935,400,000USD0000059478-16-000321
    FY 2015Yearly · 2015-12-31SegmentPharmaceutical Products Total — Oncology3,509,800,000USD0000059478-16-000321
    FY 2015Yearly · 2015-12-31SegmentPharmaceutical Products Total — Other Pharmaceuticals227,700,000USD0000059478-16-000321
    FY 2015Yearly · 2015-12-31GeographyEurope3,943,600,000USD0000059478-18-000089
    FY 2015Yearly · 2015-12-31GeographyJapan2,033,100,000USD0000059478-18-000089
    FY 2015Yearly · 2015-12-31GeographyOther Foreign Countries3,884,600,000USD0000059478-18-000089
    FY 2015Yearly · 2015-12-31GeographyUnited States10,097,400,000USD0000059478-18-000089
    FY 2014Yearly · 2014-12-31SegmentAnimal Health Products2,346,600,000USD0000059478-16-000321
    FY 2014Yearly · 2014-12-31SegmentPharmaceutical Products Total — Cardiovascular3,053,500,000USD0000059478-16-000321
    FY 2014Yearly · 2014-12-31SegmentPharmaceutical Products Total — Endocrinology6,939,000,000USD0000059478-16-000321
    FY 2014Yearly · 2014-12-31SegmentPharmaceutical Products Total — Neuroscience3,596,500,000USD0000059478-16-000321
    FY 2014Yearly · 2014-12-31SegmentPharmaceutical Products Total — Oncology3,393,000,000USD0000059478-16-000321
    FY 2014Yearly · 2014-12-31SegmentPharmaceutical Products Total — Other Pharmaceuticals287,000,000USD0000059478-16-000321
    FY 2014Yearly · 2014-12-31GeographyEurope4,506,700,000USD0000059478-17-000098
    FY 2014Yearly · 2014-12-31GeographyJapan2,027,100,000USD0000059478-17-000098
    FY 2014Yearly · 2014-12-31GeographyOther Foreign Countries3,947,700,000USD0000059478-17-000098
    FY 2014Yearly · 2014-12-31GeographyUnited States9,134,100,000USD0000059478-17-000098
    FY 2013Yearly · 2013-12-31SegmentAnimal Health Products2,151,500,000USD0000059478-16-000321
    FY 2013Yearly · 2013-12-31SegmentPharmaceutical Products Total — Cardiovascular2,923,200,000USD0000059478-16-000321
    FY 2013Yearly · 2013-12-31SegmentPharmaceutical Products Total — Endocrinology7,304,400,000USD0000059478-16-000321
    FY 2013Yearly · 2013-12-31SegmentPharmaceutical Products Total — Neuroscience7,216,200,000USD0000059478-16-000321
    FY 2013Yearly · 2013-12-31SegmentPharmaceutical Products Total — Oncology3,268,500,000USD0000059478-16-000321
    FY 2013Yearly · 2013-12-31SegmentPharmaceutical Products Total — Other Pharmaceuticals249,300,000USD0000059478-16-000321
    FY 2013Yearly · 2013-12-31GeographyEurope4,338,400,000USD0000059478-16-000321
    FY 2013Yearly · 2013-12-31GeographyJapan2,063,800,000USD0000059478-16-000321
    FY 2013Yearly · 2013-12-31GeographyOther Foreign Countries3,821,200,000USD0000059478-16-000321
    FY 2013Yearly · 2013-12-31GeographyUnited States12,889,700,000USD0000059478-16-000321
    FY 2012Yearly · 2012-12-31SegmentAnimal Health Products2,036,500,000USD0000059478-15-000100
    FY 2012Yearly · 2012-12-31SegmentPharmaceutical Products Total — Cardiovascular2,632,500,000USD0000059478-15-000100
    FY 2012Yearly · 2012-12-31SegmentPharmaceutical Products Total — Endocrinology6,810,900,000USD0000059478-15-000100
    FY 2012Yearly · 2012-12-31SegmentPharmaceutical Products Total — Neuroscience7,575,100,000USD0000059478-15-000100
    FY 2012Yearly · 2012-12-31SegmentPharmaceutical Products Total — Oncology3,281,600,000USD0000059478-15-000100
    FY 2012Yearly · 2012-12-31SegmentPharmaceutical Products Total — Other Pharmaceuticals266,800,000USD0000059478-15-000100
    FY 2012Yearly · 2012-12-31GeographyEurope4,259,700,000USD0000059478-15-000100
    FY 2012Yearly · 2012-12-31GeographyJapan2,246,200,000USD0000059478-15-000100
    FY 2012Yearly · 2012-12-31GeographyOther Foreign Countries3,784,400,000USD0000059478-15-000100
    FY 2012Yearly · 2012-12-31GeographyUnited States12,313,100,000USD0000059478-15-000100
    FY 2011Yearly · 2011-12-31SegmentAnimal Health Products1,678,600,000USD0000059478-14-000078
    FY 2011Yearly · 2011-12-31SegmentPharmaceutical Products Total — Cardiovascular2,486,400,000USD0000059478-14-000078
    FY 2011Yearly · 2011-12-31SegmentPharmaceutical Products Total — Endocrinology6,806,700,000USD0000059478-14-000078
    FY 2011Yearly · 2011-12-31SegmentPharmaceutical Products Total — Neuroscience9,723,800,000USD0000059478-14-000078
    FY 2011Yearly · 2011-12-31SegmentPharmaceutical Products Total — Oncology3,322,200,000USD0000059478-14-000078
    FY 2011Yearly · 2011-12-31SegmentPharmaceutical Products Total — Other Pharmaceuticals268,800,000USD0000059478-14-000078
    FY 2011Yearly · 2011-12-31GeographyEurope5,290,900,000USD0000059478-14-000078
    FY 2011Yearly · 2011-12-31GeographyJapan2,104,100,000USD0000059478-14-000078
    FY 2011Yearly · 2011-12-31GeographyOther Foreign Countries3,914,300,000USD0000059478-14-000078
    FY 2011Yearly · 2011-12-31GeographyUnited States12,977,200,000USD0000059478-14-000078
    FY 2010Yearly · 2010-12-31GeographyEurope5,106,400,000USD0000059478-13-000007
    FY 2010Yearly · 2010-12-31GeographyJapan1,616,600,000USD0000059478-13-000007
    FY 2010Yearly · 2010-12-31GeographyOther Foreign Countries3,487,400,000USD0000059478-13-000007
    FY 2010Yearly · 2010-12-31GeographyUnited States12,865,600,000USD0000059478-13-000007

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.